Identifying a unique chromosomal pattern to predict the gemcitabine response in patients with cholangiocarcinoma.

ABSTRACT: Cholangiocarcinoma (CCA) is an epithelial bile duct cancer frequently found at an advanced stage, leading to poor response to current therapies. Although gemcitabine (GEM) and cisplatin (CIS) are the current gold-standard for treating unresectable CCA, GEM resistance often occurs. To predict the response to GEM, we evaluated chromosomal aberrations using a chromosome microarray, and their association with GEM response by histoculture drug response assay. Our findings revealed principal component analysis and orthogonal partial-least square discriminant analysis cross validated score plot between response and non-response groups were different. Different signature patterns of chromosomes between response and non-response groups analyzed by heatmap analysis identified 34 regions of 15 chromo

SUBMITTER: Techa-Ay S 

PROVIDER: S-EPMC11978821 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature